Phase 3 Clinical Trials With Primary Completion Dates in January 2020
This is a list of Phase 3 trials with primary completion dates in January 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 2020-01-01 | Phase 3 | NCT02892149 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD) |
| AKTX | Akari Therapeutics, Plc | 2020-01-01 | Phase 3 | NCT03588026 | Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 |
| AMAG | AMAG Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT03297216 | Improving Pregnancy Outcomes With Progesterone |
| BBI | Brickell Biotech, Inc. | 2020-01-01 | Phase 3 | NCT03627468 | A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis |
| BLUE | bluebird bio, Inc. | 2020-01-01 | Phase 3 | NCT02906202 | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype |
| FLXN | Flexion Therapeutics, Inc. | 2020-01-01 | Phase 3 | NCT03529942 | Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee |
| HESG | Health Sciences Group, Inc. | 2020-01-01 | Phase 3 | NCT03444324 | Adjusted Fibrinogen Replacement Strategy |
| IRWD | Ironwood Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT03561883 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors |
| IRWD | Ironwood Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT03561090 | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors |
| MNLO | Menlo Therapeutics Inc. | 2020-01-01 | Phase 3 | NCT03677401 | Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis |
| PGNX | Progenics Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT03739684 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer |
| PRAH | PRA Health Sciences, Inc. | 2020-01-01 | Phase 3 | NCT03444324 | Adjusted Fibrinogen Replacement Strategy |
| PRGO | Perrigo Company plc | 2020-01-01 | Phase 3 | NCT04024072 | To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2020-01-01 | Phase 3 | NCT01478542 | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine |
| ZGNX | Zogenix, Inc. | 2020-01-01 | Phase 3 | NCT03299842 | A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome |
| ZGNX | Zogenix, Inc. | 2020-01-01 | Phase 3 | NCT02826863 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |